Lupus & antiphospholipid syndrome

Generic and disease-adapted cardiovascular risk scores as predictors of atherosclerosis progression in SLE

Lupus Sci MedPublished Prognostic cohort study

Study context

Population
Patients with SLE without history of cardiovascular events or diabetes mellitus (90% female, mean age 44.4±11.7 years)
Participants
124 patients
Comparison
Five generic vs three SLE-adapted cardiovascular risk (CVR) scores for predicting atherosclerosis progression
Outcome
Atherosclerosis progression (new atherosclerotic plaque development), predicted by baseline CVR scores
Follow-up
3 years
Methodological details3-year carotid and femoral US follow-up, binary logistic regression
  • 3-year carotid and femoral US follow-up
  • Binary logistic regression

Performance

As reported in the abstract

Prediction of plaque progression · mean 39.7±3.8 months
Test or modelBrier ScoreAUROCMatthews correlation coefficient (MCC)
Modified Framingham Risk Score (mFRS)0.140.800.22
QRISK30.160.750.25

Brier Score

Modified Framingham Risk Score (mFRS)0.14
QRISK30.16

AUROC

Modified Framingham Risk Score (mFRS)0.80
QRISK30.75

Matthews correlation coefficient (MCC)

Modified Framingham Risk Score (mFRS)0.22
QRISK30.25
Patients developing new atherosclerotic plaques
26 (21%)

Further findings

Determinants of plaque progression (multivariate analysis)

OR (95% CI)P value
QRISK3Independently associated with plaque progression4.24 (1.30–13.78)P = 0.016
AgeIndependently associated with plaque progression1.13 (1.06–1.21)P < 0.001
Cumulative GC doseIndependently associated with plaque progression1.04 (1.01–1.07)P = 0.010
aPLIndependently associated with plaque progression3.66 (1.24–10.80)P = 0.019

Original publication

Generic and disease-adapted cardiovascular risk scores as predictors of atherosclerosis progression in SLE. Lupus Sci Med. Published 3 March 2023. doi:10.1136/lupus-2022-000864

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.